Foundayo (orforglipron), developed by Eli Lilly, is a new, once-daily oral GLP-1 weight-loss pill approved in the UAE (second globally after the US) and expected to be available from May 2026
Topical versions and ketoconazole shampoo work on the scalp with far less drug in the bloodstream, useful if systemic side effects worry you
But if the filler list is longer than the active ingredient list, that is a red flag
last year urging the FDA to loosen restrictions on peptides
These include HSPB1 (HSP27), HSPB5 (B-crystallin), HSPB6 (HSP20), HSPB7 (cardiovascular HSP), and HSPB8 (HSP22)
No single or dual-agonist compound can replicate the combined effects on appetite regulation, insulin secretion, lipolysis, and thermogenesis that retatrutide produces in research settings